PIQ Stock Overview
Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Proteomics International Laboratories Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.66 |
| 52 Week High | AU$1.39 |
| 52 Week Low | AU$0.55 |
| Beta | 0.46 |
| 11 Month Change | -23.84% |
| 3 Month Change | -22.94% |
| 1 Year Change | -38.21% |
| 33 Year Change | -26.40% |
| 5 Year Change | 87.14% |
| Change since IPO | 184.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| PIQ | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | -5.8% | 0.7% | -0.7% |
| 1Y | -38.2% | 28.2% | 17.1% |
Return vs Industry: PIQ underperformed the Australian Life Sciences industry which returned 24.6% over the past year.
Return vs Market: PIQ underperformed the Australian Market which returned 18.3% over the past year.
Price Volatility
| PIQ volatility | |
|---|---|
| PIQ Average Weekly Movement | 10.4% |
| Life Sciences Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: PIQ has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PIQ's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Richard Lipscombe | www.proteomics.com.au |
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment.
Proteomics International Laboratories Ltd Fundamentals Summary
| PIQ fundamental statistics | |
|---|---|
| Market cap | AU$85.15m |
| Earnings (TTM) | -AU$6.38m |
| Revenue (TTM) | AU$3.28m |
26.0x
P/S Ratio-13.4x
P/E RatioIs PIQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PIQ income statement (TTM) | |
|---|---|
| Revenue | AU$3.28m |
| Cost of Revenue | AU$2.02m |
| Gross Profit | AU$1.26m |
| Other Expenses | AU$7.64m |
| Earnings | -AU$6.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 38.49% |
| Net Profit Margin | -194.62% |
| Debt/Equity Ratio | 0% |
How did PIQ perform over the long term?
See historical performance and comparison